Prescribing guide
Elfabrio (pegunigalsidase alfa-iwxj)Dosing, initial infusion rates, hypersensitivity monitoring and prior authorization criteria for Fabry diseaseFor prescribers and their offices treating fabry disease: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS. Prior authorization, Elfabrio Start Form, a site with CPR-capable medical support for initial infusions, and premedication planned case by case.
Example PA threshold
FEP example: age 18 or older, confirmed Fabry disease, prescriber agrees to monitor for hypersensitivity during infusion; 2-year approval.
Monitoring
Medical support including CPR equipment at every infusion; serum creatinine and UPCR (no schedule given); IgG and IgE ADA after hypersensitivity or IARs; lyso-Gb3 when switching with pre-existing ADA; close monitoring if cardiac function is compromised.
Support line
Chiesi Total Care 1-800-784-5840 (Monday to Friday 8 AM to 8 PM ET), fax 1-877-435-2524; as little as $0 for drug and for infusion administration on eligible commercial plans; no infusion copay or infusion assistance in MA or RI.
Give your patient their plan
A one-page handout for starting Elfabrio, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/elfabrioBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Start Form | Fax the Elfabrio Start Form to 1-877-435-2524 (the HCP support page lists 1-636-355-3610 for the order form and 1-833-656-1056 as the Chiesi Total Care phone; confirm with the program). Chiesi Total Care questions 1-800-784-5840, us.chiesitotalcare@chiesi.com. Enrollment is optional and not required to receive Elfabrio. | Start Form |
| Write the prescription on the form | Weight in kg, total dose in mg (1mg/kg actual body weight every 2 weeks), frequency, refills, infusion rate in mL/hour, and vial quantity by size. The form directs the pharmacy to dispense a 28-day supply. ICD-10-CM E75.21; method of diagnosis; prior treatment, dose and last date. | Start Form |
| Routing | The form authorizes a benefits investigation and transmittal to the appropriate pharmacy. Chiesi's access guide routes through EVERSANA Life Science Services Specialty Pharmacy (white bagging) or buy and bill via CTCPurchasing@eversana.com. | Access Resource Guide |
| Calculate and prepare | Round vials up. Warm vials 15 to 30 minutes at room temperature, no external heat. Remove an equal volume of saline from the bag first. Diluted solution: up to 24 hours refrigerated, then use within 8 hours of removal including infusion time; or 8 hours at room temperature. Do not freeze or shake. | FDA label |
| Packages | NDC 10122-160-02 (one 20mg/10mL vial), 10122-165-02 (one 5mg/2.5mL vial), 10122-160-05 (five 20mg vials), 10122-160-10 (ten 20mg vials). Store at 2 to 8°C. | FDA label |
| Billing codes | HCPCS J2508 (injection, pegunigalsidase alfa-iwxj, 1mg). Administration CPT 96365 and 96366. JW for discarded drug, JZ for zero waste where required. Guide dated 2024; payer rules vary. | Access Resource Guide |
| Copay programs | Commercial only, on-label prescription, US resident: Prescription Copay and Infusion Services Copay, each as little as $0. Government-funded plans excluded; marketplace plans are not treated as government plans. Restrictions including monthly maximums may apply. Renew by December 31 each year. | Enrollment form |
| State exclusions | Patients residing or treated in MA or RI are not eligible for copay assistance for infusion services or routine testing services. The Chiesi Total Care page also excludes them from infusion assistance, including home infusion support. | Enrollment form |
| Home infusion | Program support requires referral to home infusion by the prescribing physician. Field Reimbursement Managers assist the office with coverage, PA, appeals and denials. | Chiesi Total Care |
Prior authorization criteria and what to document
One public policy as the example: Blue Cross Blue Shield Federal Employee Program, April 1, 2026. Approval two years at a time, for both the first approval and each renewal. This policy was approved on March 6, 2026 and cites the May 2024 label, which is still the current one. It does not ask for a failed earlier treatment or a specific test result. It is here as an example of what a plan asks for, not as a rule. Other plans may ask for more.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Age | 18 years or older | Date of birth on the request | FEP Blue policy |
| Diagnosis | Fabry disease | Enzyme assay, genetic test or tissue biopsy result with date (the Start Form asks which) | FEP Blue policy |
| Monitoring attestation | Prescriber agrees to monitor for hypersensitivity reactions, including anaphylaxis, during Elfabrio administration | Statement in the request; site of care with medical support | FEP Blue policy |
| Prior ERT | Not required by FEP; recorded on the Start Form and relevant to initial rate selection and ADA risk | Agent, dose, last infusion date, infusion duration and premedication | Start Form |
| Renewal | Same criteria; approval duration 2 years | Current note confirming ongoing treatment | FEP Blue policy |
Elfabrio dosing and titration
| When | Label | Source |
|---|---|---|
| Dose | 1mg/kg actual body weight IV every 2 weeks. Medical support including CPR equipment readily available. | FDA label |
| Volume by weight | Under 70kg 150mL; 70 to 100kg 250mL; over 100kg 500mL, in 0.9% sodium chloride. | FDA label |
| Initial rate, ERT-experienced | First 4 to 6 infusions: 50mL/h (0.83mL/min), 83mL/h (1.39mL/min) or 167mL/h (2.78mL/min) by the weight bands above, about 3 hours. | FDA label |
| Initial rate, ERT-naive | First 4 to 6 infusions: 37.5mL/h (0.63mL/min), 60mL/h (1mL/min) or 83mL/h (1.38mL/min), about 4 hours, about 6 hours over 100kg. | FDA label |
| Prior ERT over 3 hours | Use the same infusion rate as the prior ERT. After the initial 4 to 6 infusions, shorten every third infusion by 30 minutes as tolerated; maintenance minimum 1.5 hours. | FDA label |
| Rate reduction | If the initial 4 to 6 infusions are tolerated, decrease duration of every third infusion in 30-minute steps to a minimum of 1.5 hours. Flush at the final rate. No other products in the same line. | FDA label |
| Mild to moderate reaction | Hold 15 to 30 minutes or slow 25% to 50% and treat. If symptoms persist, stop and consider restarting within 7 to 14 days at 25% to 50% of the reaction rate with pretreatment. Then raise 25% every third infusion to the reaction rate. | FDA label |
| Home infusion | May be considered under HCP supervision once a well-tolerated duration is reached. Keep duration constant at home; decrease only in a healthcare facility. Missed or delayed home dose: contact the HCP. | FDA label |
| Missed dose | Restart as soon as possible, then keep the 2-week interval. Do not double. | FDA label |
| Populations | Adults only; pediatric safety and effectiveness not established (PREA study ages 2 to under 18 deferred). No patients 65 or older in trials. No renal or hepatic dose guidance in the label. | FDA label |
| Other regimens | 2mg/kg every 4 weeks is approved in the EU (March 2026) but not in the US; the US dose remains 1mg/kg every 2 weeks. | Chiesi and Protalix release |
Monitoring the Elfabrio label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Each infusion | Hypersensitivity and anaphylaxis (boxed warning) | 14% hypersensitivity; 4 patients (3%) with anaphylaxis 5 to 40 minutes into the first infusion, all IgE ADA positive. Severe: stop, treat, weigh rechallenge at slower rates or desensitization | FDA label |
| Each infusion and 24 hours after | Infusion-associated reactions | 29% across trials, 32% in Trial 2 (same as agalsidase beta). 51% (19/37) if IgG ADA positive at baseline against 16% (13/84) if negative | FDA label |
| Each infusion | Compromised cardiac function in advanced Fabry disease | Higher risk of severe complications from IARs; monitor closely | FDA label |
| During treatment | Membranoproliferative glomerulonephritis | One case with immune deposits; renal function improved slowly after discontinuation but not to baseline. Monitor serum creatinine and UPCR; hold until evaluated if suspected | FDA label |
| After hypersensitivity or IARs | IgG and IgE anti-drug antibodies | Consider testing. Trial 2: 18 of 52 (all male) ADA positive at baseline, 17 of 18 neutralizing; high titers lowered drug levels, 1 patient below quantification | FDA label |
| Switching from agalsidase beta | Clinical or pharmacodynamic response | Consider plasma lyso-Gb3 in patients with pre-existing ADA. In Trial 2, median lyso-Gb3 rose about 18% in males by week 104 | FDA label |
Elfabrio drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Drug interactions | No drug interaction section in the label; expected catabolism to small peptides | FDA label |
| Contraindicated | None listed | FDA label |
| Same IV line | Do not infuse with other products in the same line | FDA label |
| Pregnancy | No human data; not expected to cause adverse outcomes as an enzyme replacement. Rabbit maternal toxicity at 3.2 times or more the MRHD. Pregnancy safety study: 1-888-661-9260 | FDA label |
| Lactation | No data on milk presence, infant effects or milk production | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe FEP policy below asks for age 18 or older, a Fabry disease diagnosis and a prescriber who agrees to watch for allergic reactions during infusions. Chiesi's Field Reimbursement Managers can help the office with denials and appeals.
- A copay you cannot payCommercial insurance: the Prescription Copay and Infusion Services Copay programs, each as little as $0. Medicare, Medicaid, TRICARE, VA and other government plans are excluded. Our help paying page lists charity funds that may cover what remains.
- Your plan came from the insurance marketplaceThe program's terms say a commercial plan bought through a marketplace or exchange does not count as government coverage, even with a federal subsidy. That means copay help may still apply.
- You live in or are treated in Massachusetts or Rhode IslandThe program's terms exclude these 2 states from copay help for infusion services and routine testing. Chiesi Total Care also offers no infusion assistance, including home infusion help, there. The Prescription Copay is not part of that exclusion.
- Home infusion support was refusedChiesi Total Care requires a referral to home infusion from your prescribing physician before it supports home infusion. Its brochure also says home infusion depends on insurance and on tolerating Elfabrio first.
- No insuranceChiesi Total Care says uninsured patients may be eligible for financial assistance. Its terms ask for household size, yearly household income and proof of income such as W2 forms, pay stubs or tax returns.
- Copay help stopped in JanuaryThe program's terms say patients must renew their eligibility by December 31st each year to keep receiving support. Call Chiesi Total Care before the year ends.
Chiesi Total Care
- Patient Service Managers and Patient Education Liaisons by phone, with pharmacists and nursing support on the wider team
- A Prescription Copay program for commercial insurance, as little as $0 for Elfabrio itself
- An Infusion Services Copay program for commercial insurance, as little as $0 for infusion supplies and administration, including home infusion, except in Massachusetts and Rhode Island
- Financial support is not open to anyone with Medicare, Medicaid, VA or other government coverage, though nonfinancial help still is
- Infusion assistance: help finding an infusion facility, delivery of the medicine to where you need it, and a home infusion eligibility review. It needs a prescriber referral for home infusion and is not offered in Massachusetts or Rhode Island
- Possible financial assistance for people with no insurance. Enrollment uses the Patient Enrollment and Consent Form, faxed to 1-877-435-2524
Questions prescribers' offices ask about Elfabrio
What is the Elfabrio dose for Fabry disease?
1mg/kg actual body weight IV every 2 weeks, per the May 2024 label. Round vials (20mg/10mL and 5mg/2.5mL, 2mg/mL) up to the next whole number, dilute in 0.9% sodium chloride to 150, 250 or 500mL by weight, and infuse through a 0.2 micron low protein-binding in-line filter. Do not double a missed dose.
How long are the initial Elfabrio infusions?
For the initial 4 to 6 infusions the May 2024 label fixes the rate by weight: ERT-experienced 50, 83 or 167mL/h (about 3 hours); ERT-naive 37.5, 60 or 83mL/h (about 4 hours, about 6 hours over 100kg). Patients coming from an ERT infused over 3 hours start at that same rate. Thereafter every third infusion may be shortened by 30 minutes, to a 1.5-hour minimum.
What premedication does Elfabrio need?
None is mandated; the May 2024 label says to consider antihistamines, antipyretics and/or corticosteroids. In ERT-experienced patients premedicated on prior ERT, consider similar pretreatment for the first several infusions, then a stepwise taper after 4 to 6 tolerated infusions. Up to 40% of trial patients were pretreated at least once.
What monitoring does Elfabrio need?
Per the May 2024 label: CPR-capable medical support during every infusion (boxed warning), serum creatinine and urine protein to creatinine ratio for membranoproliferative glomerulonephritis, IgG and IgE ADA in patients with hypersensitivity or IARs, and lyso-Gb3 or clinical response when switching from agalsidase beta with pre-existing ADA. No lab schedule is specified.
What do insurers ask for to approve Elfabrio?
The FEP policy 5.30.087, effective April 1, 2026 and citing the May 2024 label, asks for age 18 or older, a Fabry disease diagnosis, and prescriber agreement to monitor for hypersensitivity including anaphylaxis during administration. Approval and renewal are 2 years on the same criteria; no step therapy or lab threshold.
Free email alert
Get an email when the Elfabrio label changes
One email the day the FDA revises the Elfabrio prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Elfabrio only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- ELFABRIO (pegunigalsidase alfa-iwxj) injection, for intravenous use, prescribing information, revised May 2024, Chiesi USA, via DailyMed, 2024-07-08.
- ELFABRIO (pegunigalsidase alfa-iwxj) injection, for intravenous use, prescribing information, revised 5/2023, FDA, Drugs@FDA, 2023-05-09.
- BLA 761161 approval letter, Elfabrio (pegunigalsidase alfa-iwxj), FDA, 2023-05-09.
- Elfabrio® (pegunigalsidase alfa-iwxj) support for Patients & Caregivers: Chiesi Total Care℠, Chiesi USA, 2026-11-07.
- Chiesi Total Care Patient Enrollment and Consent Form (PP-RA-00363 V2.0, July 2025), Chiesi USA, 2025-08-04.
- Chiesi Total Care Patient Support Program Terms and Conditions (PP-EF-0130 V3.0), Chiesi USA, 2023-10-02.
- Elfabrio® Start Form (PP-RA-01080 V1.0), Chiesi USA, 2025-08-21.
- Elfabrio patient brochure, For adults with Fabry disease (PP-RA-00032 V2.0), Chiesi USA, 2025-12-04.
- Patient Support & Access Services, Chiesi USA, 2026-11-07.
- ERT Option Overview for Fabry disease, Chiesi USA, 2026-11-07.
- Elfabrio Access Resource Guide (PP-EF-0326 V5.0), Chiesi USA, 2024-10-02.
- Pharmacy Policy 5.30.087, Elfabrio, Blue Cross Blue Shield Federal Employee Program, 2026-04-01.
- Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa), Chiesi and Protalix, via BioSpace (GlobeNewswire), 2026-03-09.
A reference drawn from the July 8, 2024 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 7, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.